IP Verse

Treatment Of Cancer

Patent No. EP4096717 (titled "Treatment Of Cancer") was filed by Innate Pharma on Jan 28, 2021. The application was issued on Dec 11, 2024.

Patent Summary

Antibody-drug conjugates (ADCs) targeting Nectin-4 for treating cancers with low or heterogeneous Nectin-4 expression, including bladder, breast, lung, and pancreatic cancers. The ADCs comprise a Nectin-4-binding antibody conjugated to a camptothecin analogue, such as exatecan, through a cleavable linker. The ADCs can be used in patients with Nectin-4-expressing cancers who have received prior chemotherapy or have resistance to HER2-targeted therapies. The ADCs exhibit improved efficacy and reduced toxicity compared to existing Nectin-4-targeted ADCs, enabling treatment of patients with low or moderate Nectin-4 expression levels.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANSep 11, 2025DORRIES
ARROWHOUSESep 10, 2025VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4096717

INNATE PHARMA
Application Number
EP21702624A
Filing Date
Jan 28, 2021
Status
Granted And Under Opposition
Nov 8, 2024
Publication Date
Dec 11, 2024
External Links
Slate, Register , Google Patents